Our current study had following novel findings: 1) we reported that tumor infiltration of neutrophils was positive correlation with clinical outcome in patients with RCC; 2) cabozantinib treatment induced anti-tumor neutrophils in murine RCC model; 3) importantly, our work demonstrated that CD8+ T cells also participated in the cabozantinib mediated anti-tumor process. The gene discussed is CD8A; the disease is renal cell adenocarcinoma.